Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Northern Trust Corp

Northern Trust Corp boosted its holdings in Insmed Incorporated (NASDAQ:INSM) by 19.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,750,642 shares of the biopharmaceutical company’s stock after acquiring an additional 290,678 shares during the quarter. Northern Trust Corp owned 0.98% of Insmed worth $120,864,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in INSM. Steward Partners Investment Advisory LLC lifted its position in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC raised its stake in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management acquired a new stake in shares of Insmed in the fourth quarter valued at $47,000. Smartleaf Asset Management LLC boosted its stake in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Insmed during the fourth quarter worth about $86,000.

Insmed Stock Performance

Shares of INSM opened at $72.30 on Friday. The company has a market capitalization of $13.15 billion, a PE ratio of -12.93 and a beta of 1.07. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The company’s 50 day moving average price is $73.42 and its 200 day moving average price is $73.46. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Research analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Tuesday, April 22nd. Morgan Stanley upped their price target on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Stifel Nicolaus reduced their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.00.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 45,605 shares of the firm’s stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $80.90, for a total transaction of $3,689,444.50. Following the transaction, the chief operating officer now owns 189,157 shares in the company, valued at approximately $15,302,801.30. This trade represents a 19.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $77.94, for a total transaction of $1,461,375.00. Following the completion of the sale, the chief executive officer now owns 379,534 shares of the company’s stock, valued at $29,580,879.96. This represents a 4.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 387,487 shares of company stock valued at $30,825,692 in the last three months. Corporate insiders own 3.00% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.